Subcutaneous Allergen Immunotherapy for Allergic Disease

Examining Efficacy, Safety and Cost-Effectiveness of Current and Novel Formulations

Linda Cox; Moisés Calderón; Oliver Pfaar

Disclosures

Immunotherapy. 2012;4(6):601-616. 

In This Article

Future Perspective

In the next 5–10 years it is likely that SCIT will involve more modified formulations, such as peptide fragments or modified extracts in conjunction with immune-stimulatory adjuvants. In addition to improved efficacy and safety, these modified extracts/vaccines may allow for shorter courses of treatment (e.g., four to six injections). The short-course treatments may be more 'attractive' to patients who find it difficult to adhere to a 3–5 year SCIT regimen that requires regular office visits or to those who dislike taking daily sublingual tablets or solution. This may result in a much larger percentage of allergic patients subscribing to allergen immunotherapy than the small percentage that currently receives it (~5% of the allergic population).[82]

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....